The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Putilina M.V.

Pirogov Russian National Research Medical University

The use of neuropeptides of animal origin in the treatment of neurological diseases

Authors:

Putilina M.V.

More about the authors

Read: 8588 times


To cite this article:

Putilina MV. The use of neuropeptides of animal origin in the treatment of neurological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9):37‑42. (In Russ.)
https://doi.org/10.17116/jnevro202312309137

Recommended articles:
Prevention of acute kidney injury in cardiac surgery. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):83-89

References:

  1. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707. https://doi.org/10.1016/j.bmc.2017.06.052
  2. Lee AC, Harris JL, Khanna KK, Hong JH. A Comprehensive Review on Current Advances in Peptide Drug Development and Design. Int J Mol Sci. 2019;20(10):2383. https://doi.org/10.3390/ijms20102383
  3. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325.  https://doi.org/10.1038/s41573-020-00135-8
  4. Khavinson VKh. Medicinal peptide preparations: past, present, future. Clinical Medicine. 2020;98(3):165-177. (In Russ.). https://doi.org/10.30629/0023-2149-2020-98-3-165-177
  5. Putilina MV. Endothelium as a target for new therapeutic strategies in cerebral vascular diseases. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(10):122-130. (In Russ.). https://doi.org/10.17116/jnevro2017117101122-130
  6. Gomazkov OA. Functional biochemistry of regulatory peptides. M.: Nauka; 1993. (In Russ.).
  7. Nam SH, Park J, Koo H. Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides. Arch Pharm Res. 2023;46(1):18-34.  https://doi.org/10.1007/s12272-022-01425-y
  8. Moretta A, Scieuzo C, Petrone A, et al. Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields. Front Cel Infect Microbiol. 2014;11(8):456-462.  https://doi.org/10.3389/fcimb.2021.668632
  9. Apostolopoulos V, Bojarska J, Feehan J, et al. Smart therapies against global pandemics: A potential of short peptides. Front Pharmacol. 2025;13:914467. https://doi.org/10.3389/fphar.2022.914467
  10. Zhou X, Smith QR, Liu X. Brain-penetrating peptides and peptide-drug conjugates for overcoming the blood-brain barrier and combating diseases of the central nervous system. WIRES Nanomed Nanobiotechnol. 2021;12(34):1695. https://doi.org/10.1002/wnan.1695
  11. Zhao L, Liu JW, Shi HY, Ma YM. Neural stem cell therapy for brain disease. World J Stem Cells. 2021 Sep 26;13(9):1278-1292. https://doi.org/10.4252/wjsc.v13.i9.1278
  12. Kulesh AA, Shestakov VV. Post-stroke cognitive impairment and the possibility of treatment with cellex. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(5):38-42. (In Russ.). https://doi.org/10.1007/s11055-017-0490-3
  13. Gromova OA, Torshin IIu, Gogoleva IV. Mechanisms of neurotrophic and neuroprotective effects of cerebrolysin in cerebral ischemia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;114(3-2):43-50. (In Russ.).
  14. Putilina MV. Current concepts about small vessel disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019;119(11):65-73. (In Russ.). https://doi.org/10.17116/jnevro201911911165
  15. Bornstein NM, Guekht A, Vester J, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640.  https://doi.org/10.1007/s10072-017-3214-0
  16. Gavrilova SI, Alvarez A. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use. Med Res Rev. 2020;45(12):45-51.  https://doi.org/10.1002/med.21722
  17. Gomazkov OA. Cortexin. Molecular mechanisms and targets of neuroprotective activity. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(8):99-104. (In Russ.). https://doi.org/10.17116/jnevro20151158199-104
  18. Pinelis VG, Storozhevykh TP, Surin AM, et al. Neuroprotective effects of cortagen, cortexin and semax on glutamate neurotoxicity J Peptide Sci. 2008;14(8):159-160. 
  19. Soudy R, Kimura R, Patel A. Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model. Sci Rep. 2019;9:10942. https://doi.org/10.1038/s41598-019-47255-9
  20. Yakovlev AA, Gulyaeva NV. Molecular partners of cortexin in the brain. Neurochemistry. 2017;34(1):91-96. (In Russ.). https://doi.org/10.7868/S1027813316040166
  21. Yakovlev AA, Lyzhin AA, Khaspekov LG, et al. The peptide-based drug cortexin inhibits brain caspase-8. Biochemistry (Moscow), Supplement Series B: Biomed Chem. 2017;11(2):134-138.  https://dx.doi.org/10.1134/s1990750817020111
  22. Lee J, Kim C. Peptide Materials for Smart Therapeutic Applications. Macromol Res. 2021;29:2-14.  https://doi.org/10.1007/s13233-021-9011-x
  23. Putilina MV, Mutovina ZYu, Kurushina OV, et al.Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022;122(1):84-90. (In Russ.). https://doi.org/10.17116/jnevro202212201184
  24. Fedin AI, Bel’skaia GN, Kurushina OV, et al. Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;118(9):35-42. (In Russ.). https://doi.org/10.17116/jnevro201811809135
  25. Putilina MV. Pathogenetic approaches to the treatment of sleep disorders in comorbid patients. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022;122(11):11-16. (In Russ.). https://doi.org/10.17116/jnevro202212211111
  26. Tyurenkov IN, Kurkin DV, Kalatanova AV, et al. Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment, cerebral circulation and morphological changes in the hippocampus of rats with chronic brain ischemia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(8):83-89. (In Russ.). https://doi.org/10.17116/jnevro202012008183
  27. Gromova OA, Torshin IYu, Putilina MV, et al. Choice of neuroprotective therapy regimens in patients with chroniccerebral ischemia, taking into account the synergy of drug interactions. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(8):42-50. (In Russ.). https://doi.org/10.17116/jnevro202012008142
  28. Putilina MV, Teplova NV. Drug synergism as a basis for rational neuroprotection. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022;122(5):17-22. (In Russ.). https://doi.org/10.17116/jnevro202212205117
  29. Lubell WD. Peptide-Based Drug Development. Biomedicines. 2022;10(8):2037. https://doi.org/10.3390/biomedicines10082037
  30. Putilina MV. Combined neuroprotective therapy for cerebrovascular diseases. Doctor. 2012;4(3):69-73. (In Russ.).

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.